LUN H. Lundbeck A/S

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Valby, Denmark, 9 May 2019 – H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck.

1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Deborah Dunsire
2. Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification/Amendment Initial notification
3. Details of  the issuer,  emission  allowance  market participant,

auction platform, auctioneer or auction monitor
a) Name H. Lundbeck A/S
b) LEI code 5493006R4KC2OI5D3470
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial

instrument, type of instrument



Identification code
Shares



 



 



DK 0010287234
b) Nature of the transaction Purchase of shares
c) Price(s) and volume(s) Price(s) Volume(s)
    272.62 3,500
d) Aggregated information

- Aggregated volume

- Price
 
e) Date of the transaction 2019-05-09
f) Place of the transaction NASDAQ Copenhagen XCSE



1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Henrik Andersen
2. Reason for the notification
a) Position/status Member of the Board of Directors
b) Initial notification/Amendment Initial notification
3. Details of  the issuer,  emission  allowance  market participant,

auction platform, auctioneer or auction monitor
a) Name H. Lundbeck A/S
b) LEI code 5493006R4KC2OI5D3470
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial

instrument, type of instrument



Identification code
Shares



 



 



DK 0010287234
b) Nature of the transaction Purchase of shares
c) Price(s) and volume(s) Price(s) Volume(s)
    287.90 3,500
d) Aggregated information

- Aggregated volume

- Price
 
e) Date of the transaction 2019-05-08
f) Place of the transaction NASDAQ Copenhagen XCSE

 

 

 

Persons under an obligation to report are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.

Closely associated persons/entities means inter alia:

  • spouse or cohabitant
  • dependent children
  • legal entities in which the executive has a controlling influence.

Lundbeck contacts

Investors:

Palle Holm Olesen

Vice President, Investor Relations



Media:

Mada Kronborg

Senior Director, Corporate Communication



About H. Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.

Read more at . 

Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more than 100 countries. Our research center is based in Denmark and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 18,1 billion in 2018 (EUR 2,4 billion; USD 2,8 billion).

For additional information, we encourage you to visit our corporate site  and connect with us on Twitter at  and via .

Attachment

EN
09/05/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on H. Lundbeck A/S

Rune Majlund Dahl
  • Rune Majlund Dahl

Lundbeck (Buy, TP: DKK48.00) - Focus on Vyepti sales

We forecast Q1 sales c0.5% above consensus and an adj. EBITDA margin of 31.3%. We expect the strategic brands sales to rise by 18.3% YOY, including Vyepti sales of DKK913m (c2.2% above consensus). We forecast unchanged 2025 guidance for CER figures. From the pipeline, the FDA AdCom for Rexulti in PTSD is still unscheduled and the PROCEED trial has recently been expanded to additional IV doses. We reiterate our BUY, but have cut our target price to 48 (56).

Rune Majlund Dahl
  • Rune Majlund Dahl

Lundbeck (Buy, TP: DKK56.00) - PTSD decision getting closer

Lundbeck reached the high-end of its full-year guidance, with Q4 sales of DKK5,541m and an adj. EBITDA margin of 20.8%. Strategic brands’ Q4 sales were slightly below our forecast and consensus, with only Brintellix beating our estimate. The 2025 guidance is for sales growth of 7–10% at constant exchange rates (CER) and adj. EBITDA growth of 5–11% at CER. We view the upcoming Rexulti PTSD FDA Advisory Committee Meeting (due in H1) as the next share-price catalyst. We reiterate our BUY and DKK56 ...

Rune Majlund Dahl
  • Rune Majlund Dahl

Lundbeck (Buy, TP: DKK56.00) - Solid Q4e; PTSD decision ahead

We forecast Q4 sales of DKK5,631m (consensus DKK5,629m) and adj. EBITDA of DKK1,155m (consensus DKK1,147m). For strategic brands, we estimate sales of DKK4,493m (c1.1% above consensus). We expect 2025 guidance for growth of CER sales of 3–6% and adj. EBITDA of 3–7%. We believe investor focus will be on the upcoming Rexulti PTSD FDA Advisory Committee Meeting (ADCOM), due in H1. We reiterate our BUY and DKK56 target price.

Rune Majlund Dahl
  • Rune Majlund Dahl

Lundbeck (Buy, TP: DKK56.00) - Focusing on strategic brands

The Q3 sales beat reflected a strong result in strategic brands, leading to an outperformance on adj. EBITDA. We expect continued momentum in strategic brands, with Q4e sales growth of 17.4% YOY. The 2024 guidance was narrowed for CER revenue growth of 12–14% (previously 11–14%) and CER adj. EBITDA growth of 17–20% (15–20%) and we find the top end of the guidance reachable. We reiterate our BUY and DKK56 target price.

Rune Majlund Dahl
  • Rune Majlund Dahl

Lundbeck (Buy, TP: DKK56.00) - Strategic brands in focus

Lundbeck recently released company consensus for Q3. Our revenue forecast of DKK5,502m is c0.5% above, driven by strategic brands (we estimate 21.6% revenue growth YOY), and we forecast an adj. EBITDA margin of 29.4% (consensus 28.9%). We expect the 2024 guidance for 11–14% revenue growth and 15–20% adj. EBITDA growth at CER to be unchanged. We reiterate our BUY and DKK56 target price.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch